Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome

Krystallenia I Alexandraki,1,2 Eleni A Kandaraki,3,4 Kalliopi-Anna Poulia,5 Christina Piperi,6 Eirini Papadimitriou1 and Theodoros G Papaionannou7

1. Medical School, National and Kapodistrian University of Athens, Athens, Greece; 2. Eleitho Practice, Athens, Greece; 3. Medical School, European University Cyprus (EUC), Nicosia, Cyprus; 4. Department of Endocrinology & Diabetes Mellitus, HYGEIA Hospital, Athens, Greece; 5. Department of Nutrition, Laiko General Hospital, Athens, Greece; 6. Department of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 7. First Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome, with long-term sequelae from birth to senescence. The long-term effects of PCOS are attributed to several metabolic aberrations ensuing the syndrome. In a systematic review of literature regarding the cardiovascular risk factors that accompany PCOS, we found that macrovascular function has been assessed by flow-mediated dilatation (FMD), microvascular function by venous occlusion plethysmography (VOP), and arterial structure by ultrasonographic assessment of intima-media thickness (IMT) usually of the carotid artery. Contradictory results have been reported; however, in most studies, endothelial dysfunction, an early marker of atherosclerosis assessed either by haemodynamic methods such as FMD or by biochemical methods such as endothelin-1 levels, was found to be impaired. VOP is a less-studied method, with few indices altered. IMT was found to be altered in most of the included studies, but the population was more heterogeneous. Inflammatory markers, including C-reactive protein, were also found to be altered in most studies. On the other hand, a number of interventions have been shown beneficial for the markers of cardiovascular risk, in the context of insulin-sensitizers. However, other interventions such as oral contraceptive pills or statins did not consistently show a similar beneficial effect. In summary, the early identification and eventual treatment of cardiovascular clinical and biochemical risk factors may be used in clinical practice to prevent potential ‘silent’ triggers of cardiovascular disease.

Keywords
Flow-mediated dilatation, intima-media thickness, nitrate-mediated dilatation, polycystic ovary syndrome, arterial stiffness, metformin, insulin resistance, insulin sensitizers, inositols, spironolactone

Disclosure: Krystallenia I Alexandraki, Eleni A Kandaraki, Kalliopi-Anna Poulia, Christina Piperi, Eirini Papadimitriou and Theodoros G Papaioanannou have no financial or non-financial relationships or activities to declare in relation to this article.

Review Process: Double-blind peer review.

Compliance with Ethics: This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Authorship: The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Access: This article is freely accessible at touchENDOCRINOLOGY.com. © Touch Medical Media 2021

Received: 23 March 2020
Accepted: 22 June 2020
Published Online: 12 April 2021
Citation: touchREVIEWs in Endocrinology, 2021;17(1):37–53
Corresponding Author: Krystallenia I Alexandraki, Eleitho Practice, 132nd Kifisias Avenue, Amarousion, Attiki, Athens, Greece. E: alexandraki@gmail.com

Support: No funding was received in the publication of this article.

Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome, considered the most common endocrinopathy in women of reproductive age, with a prevalence of 6–8% in premenopausal women.1,2 However, long-term sequelae are extended beyond the reproductive axis, being present from birth to senescence. Consequently, early detection and treatment options are in high demand to prevent long-term complications. This review aims to summarize the evidence published regarding the cardiovascular risk factors that accompany PCOS.

We systematically searched and reviewed all relevant publications in PubMed up to February 2020 using the terms ‘flow-mediated dilatation and PCOS’ (55 results), ‘plethysmography and PCOS’ (4 results), and ‘intima-media thickness and PCOS’ (116 results). Reviews and studies without a control group to be compared with the PCOS group were excluded. Finally, we selected 104 research studies investigating cardiovascular risk factors in PCOS compared to controls, published between 1996 and 2020, and 35 studies (14 common) investigating cardiovascular risk factors in women with PCOS before and after therapeutic interventions, published between 2005 and 2020 (Tables 1 and 2, Figure 1).

Definition of polycystic ovary syndrome

PCOS is a heterogeneous syndrome that has remained a syndrome of unknown aetiology since its first description by Stein and Leventhal 85 years ago, and is probably one of the least understood endocrine disorders in women.1,2 The clinical phenotype is determined by genetic and environmental factors.1,3 In 2009, after a systematic review of the published literature, the Androgen Excess Society suggested that PCOS should be defined by the presence of hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo-anovulation and/or polycystic ovaries), and the exclusion of related disorders. Nevertheless, some endocrinologists have also addressed the possibility that there may be forms of PCOS without overt evidence of hyperandrogenism, but more data were required before validating this supposition.1,4 Therefore, PCOS remains a diagnosis of exclusion, and it is evident that PCOS is a polyprismatic condition. The prevalence of different phenotypes and the actual clinical significance of different laboratory and imaging variables remain under continuous investigation in an effort to identify markers of the syndrome’s severity and predictors of its long-term sequelae.
Table 1: Studies of cardiovascular risk markers (microvascular and macrovascular function, arterial structure) and inflammatory studies in polycystic ovary syndrome

| Studies                        | Marker                                                                 | Findings                                                                 | PCOS, n | Controls, n |
|--------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|---------|-------------|
| Guzik, 1996                   | IMT                                                                    | Impaired                                                                 | 16      | 16          |
| Mather, 2000                  | FMD                                                                    | No alteration                                                            | 18      | 19          |
| Talbott, 2000                 | IMT                                                                    | Impaired                                                                 | 125     | 142         |
| Diamanti-Kandarakis, 2001     | ET-1                                                                   | Impaired                                                                 | 43      | 17          |
| Paradisi, 2001                | Leg blood flow by leg plethysmography                                   | Impaired                                                                 | 12      | 13          |
| Kelly, 2002                   | PWV (brachial artery, aorta), wire myography (ex vivo norepinephrine response on insulin infusion) | PWV on brachial artery and insulin action on microvasculature impaired   | 19      | 12          |
| Lakhanì, 2004                 | CIMT, femoral IMT                                                       | CCA IMT, femoral IMT impaired (not bulb CIMT)                           | 19      | 12          |
| Orio, 2004                    | FMD, NID, IMT                                                          | Impaired                                                                 | 30      | 30          |
| Talbott, 2004                 | IMT, CRP                                                               | Impaired                                                                 | 47      | 59          |
| Tankun, 2004                  | FMD, NID, CRP                                                          | Impaired                                                                 | 37      | 25          |
| Bickerton, 2005               | Venous occlusion plethysmography (forearm), CRP                         | No alteration                                                            | 11      | 12          |
| Carmassi, 2006                | Blood flow in microvasculature on forearm volume by the water displacement method | Impaired endothelial-dependent vasodilation in insulin resistant only   | 16      | 6           |
| Diamanti-Kandarakis, 2005     | FMD, NID, ET-1                                                         | FMD, ET-1 impaired                                                       | 20      | 20          |
| Kravariti, 2005               | FMD, NID                                                               | Impaired                                                                 | 62      | 17          |
| Lakhanì, 2005                 | Microvascular function by forearm skin microvascular erythrocyte flux responses, to acetylcholine and sodium nitroprusside (laser Doppler) | Impaired                                                                 | 12      | 12          |
| Meyet, 2005                   | FMD, IMT, PWV (brachial artery)                                        | PWV, FMD impaired                                                       | 100     | 20          |
| Vryonidou, 2005               | IMT                                                                    | Impaired                                                                 | 75      | 55          |
| Yural, 2005                   | IMT                                                                    | Impaired                                                                 | 43      | 43          |
| Alexandraki, 2006             | FMD, NID, IMT, venous occlusion plethysmography on forearm (time to peak hyperaemia) | FMD, time to peak hyperaemia impaired                                    | 27      | 27          |
| Brinkworth, 2006              | FMD, PWV (brachial artery, aorta), microvascular function (wire myography; ex vivo norepinephrine response on insulin infusion), CRP | No alteration                                                            | 12      | 10          |
| Carmina, 2006                 | FMD, IMT                                                               | Impaired                                                                 | 50      | 50          |
| Cascella, 2006                | IMT, CRP                                                               | Impaired                                                                 | 50      | 50          |
| Dagre, 2006                   | Venous occlusion plethysmography on forearm (duration of reactive hyperaemia) | Impaired                                                                 | 27      | 13          |
| Diamanti-Kandarakis, 2006     | FMD, NID, CRP; ET-1, sICAM-1, sVCAM-1                                  | FMD, ET-1, sICAM-1, sVCAM-1, CRP impaired                               | 25      | 25          |
| Sorensen, 2006                | FMD, NID (by CMR)                                                      | FMD impaired                                                            | 14      | 13          |
| Beckman, 2007                 | FMD, NID                                                               | No alteration                                                            | 10      | 19          |
| Dokras, 2007                  | Forearm blood flow by VOP in response to endothelium dependent and endothelium independent dilatators | No alteration                                                            | 24      | 22          |
| Lowenstein, 2007              | PWA*                                                                   | No alteration                                                            | 31      | 33          |
| Luque-Ramirez, 2007           | IMT                                                                    | Impaired                                                                 | 40      | 20          |
| Cascella, 2008                | FMD, IMT, CRP, WBC                                                     | Impaired                                                                 | 200     | 100         |
| Erdoğan, 2008                 | IMT, CRP                                                               | CRP impaired                                                             | 68      | 26          |
| Trakakis, 2008                | IMT, flow velocities, resistance index in both extracranial carotid and VA, in the AO and in the RA | IMT, peak systolic velocity increased; end diastolic velocity in VA and RA, in AO and in left extracranial carotid system increased; PR of AO and right external carotid artery increased; in RA and in left VA, PR decreased | 53      | 53          |
| Heutling, 2008                | IMT, CRP IL-6                                                          | IMT and CRP impaired                                                     | 83      | 39          |
| Karadeniz, 2008               | IMT, CRP                                                               | CRP impaired                                                             | 91      | 74          |
| Adali, 2010                   | IMT                                                                    | No alteration                                                            | 50      | 25          |
| Arikan, 2009                  | FMD, IMT                                                               | No alteration                                                            | 39      | 30          |
| Carmina, 2009                 | IMT                                                                    | Impaired                                                                 | 95      | 90          |
| Studies                        | Marker                                                                 | Findings                                                                 | PCOS, n | Controls, n |
|-------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|---------|-------------|
| Ciccone, 200940               | IMT (carotid and common femoral arteries)                              | No alteration                                                            | 29      | 26          |
| Cussons, 200941               | FMD, arterial stiffness by PWV and AI                                  | FMD impaired; arterial stiffness no impairment                             | 19      | 19          |
| Erdogan, 200942               | IMT, CRP                                                               | No alteration                                                            | 88      | 119         |
| Kaye, 200943                  | IMT, CRP                                                               | Impaired                                                                 | 46      | 46          |
| Luque-Ramírez, 200944         | FMD, NID                                                               | No alteration                                                            | 40      | 20          |
| Mancini, 200945               | FMD, ET-1                                                              | FMD more increased in lean controls; ET-1 increased in obese PCOS versus lean controls | 24      | 20          |
| Moran, 200946                 | FMD, CRP                                                               | No alteration                                                            | 80      | 27          |
| Soares, 200947                | CCA stiffness index (β), distensibility and IMT, FMD on brachial artery by US; IL-6, TNF-α, CRP | Carotid stiffness (β) index impaired (increased); carotid distensibility impaired (decreased); IMT, FMD not impaired | 40      | 50          |
| Costa, 200848                 | IMT, CRP                                                               | IMT impaired                                                             | 57      | 37          |
| Kaya, 201049                  | IMT, CRP; IL-6, IL-18                                                  | Impaired                                                                 | 60      | 60          |
| Ketel, 201050                 | Arterial stiffness obtained by US (distensibility and compliance of carotid, femoral, brachial arteries); carotid elastic modulus; pulse wave transit time analyzes (carotid-femoral pulse wave velocity and aortic augmentation index) | No alteration                                                            | 30      | 30          |
| Battaglia, 201151             | IMT, ophthalmic artery pulsatility index                               | Ophthalmic artery pulsatility index impaired                              | 49      | 40          |
| Caglar, 201152                | IMT, CRP                                                               | Impaired                                                                 | 61      | 21          |
| Cakir, 201153                 | IMT                                                                    | Impaired                                                                 | 52      | 36          |
| Coksuer, 201144               | IMT                                                                    | Impaired                                                                 | 31      | 33          |
| Mohammadi, 201155             | FMD, IMT                                                               | Impaired                                                                 | 46      | 45          |
| Naka, 201157                  | FMD                                                                    | Impaired                                                                 | 43      | 14          |
| Naka, 201158                  | FMD                                                                    | Impaired                                                                 | 13      | 14          |
| Pamuk, 201059                 | IMT, CRP                                                               | No alteration                                                            | 35      | 31          |
| Pepene, 201160                | IMT, CRP                                                               | Impaired                                                                 | 64      | 20          |
| Soyman, 201161                | FMD                                                                    | Impaired                                                                 | 30      | 30          |
| Studen, 201162                | FMD, NID                                                               | FMD impaired                                                             | 30      | 20          |
| Tan, 201163                   | IMT, CRP                                                               | Impaired                                                                 | 83      | 39          |
| Cakir, 201264                 | IMT                                                                    | Impaired                                                                 | 46      | 28          |
| Cakir, 201365                 | IMT, CRP                                                               | Impaired                                                                 | 50      | 39          |
| Karabulut, 201266             | IMT                                                                    | No alteration                                                            | 46      | 43          |
| Karoli, 201267                | FMD, IMT, CRP                                                          | FMD, IMT impaired                                                        | 50      | 50          |
| Pepene, 201268                | FMD, IMT, CRP                                                          | FMD, IMT impaired                                                        | 26      | 29          |
| Pepene, 201269                | FMD, IMT, CRP                                                          | FMD impaired in lean                                                     | 69 (19 lean) | 33 (16 lean) |
| Zueff, 201270                 | FMD, IMT, carotid stiffness index                                      | No alteration                                                            | 45      | 45          |
| Abali, 201371                 | IMT                                                                    | Impaired                                                                 | 35      | 37          |
| Alimem, 201372                | IMT                                                                    | Impaired                                                                 | 44      | 44          |
| Barcellos, 201373             | FMD, IMT, CAC                                                          | No alteration                                                            | 25      | 23          |
| Cek, 201374                   | FMD, IMT                                                               | Impaired                                                                 | 44      | 42          |
| Kahal, 201375                 | IMT, endothelial reactive hyperaemic index, CRP, sE-selectin, sP-selectin, sVCAM-1, sICAM-1 | No alteration                                                            | 21      | 19          |
| Kim, 201376                   | IMT                                                                    | No alteration                                                            | 56      | 56          |
| Tan, 201377                   | IMT, CRP, TNF-α                                                        | IMT, TNF-α impaired                                                      | 83      | 39          |
| Teng, 201378                  | IMT                                                                    | No alteration                                                            | 42      | 43          |
| Yildir, 201379                | IMT, CRP                                                               | Impaired                                                                 | 34      | 20          |
| Berberoglu, 201480            | IMT                                                                    | No alteration                                                            | 42      | 20          |
| Buyukkaya, 201481             | IMT                                                                    | No alteration                                                            | 25      | 25          |
Metabolic and related features associated with polycystic ovary syndrome

The long-term effects of PCOS are attributed to several metabolic aberrations ensuing the syndrome, including insulin resistance and hyperinsulinemia, type 2 diabetes mellitus (T2DM), dyslipidemia and other risk factors for cardiovascular disease (CVD).129–132

Insulin resistance is regarded as the cornerstone of the syndrome’s pathophysiology and seems to have detrimental effects on several target organs, justifying the characterization of PCOS as a multisystem disorder. An overlap between PCOS and insulin resistance or metabolic syndrome has been described, since these two clinical entities share common characteristics such as abdominal obesity, elevated serum triglyceride levels, low serum high-density lipoprotein cholesterol (HDL-C) levels, abnormal blood pressure (BP) and impaired carbohydrate metabolism.130,140 The prevalence of metabolic syndrome in women with PCOS130 and seems to be independent from obesity. 137–139

With regard to the criteria used to determine insulin resistance, it is known that the hyperinsulinemic euglycemic clamp (HEC) remains the gold standard, but due to its complexity and invasiveness it is rarely used in practice compared with other methods, which may be less precise but are non-invasive and widely acceptable in clinical research.141

Hyperinsulinaemia and insulin resistance play a critical role in the pathogenesis of PCOS and metabolic syndrome, which are both associated with a high risk for T2DM, hypertension, hyperlipidaemia and atherosclerosis. Insulin resistance is present in approximately 50–75% of women with PCOS130 and seems to be independent from obesity.137–139

In 50% of women with PCOS, insulin resistance appears to be related to abnormal insulin-independent serine phosphorylation of the β-subunit of insulin receptor.131,132 Reduced activity of phosphatidylinositol 3-kinase (PI3K) was also found in muscle tissue of these patients.131

Table 1: Continued

| Studies | Marker | Findings | PCOS, n | Controls, n |
|---------|--------|----------|--------|------------|
| Gencer, 20148 | Arterial stiffness and aortic stiffness (p-index), aorta distensibility, IMT | IMT, aortic stiffness (p-index) and distensibility impaired | 50 | 44 |
| Gulen, 20148 | FMD, IMT | Impaired | 50 | 50 |
| Karbek, 20148 | IMT | Impaired | 40 | 43 |
| Rees, 20148 | Arterial stiffness (aPWW), IMT, diastolic function (longitudinal tissue velocity; ‘a’-‘a’) | No alteration | 84 | 95 |
| Tan, 20148 | IMT, CRP, IL-6, TNF-α | IMT, CRP impaired | 83 | 39 |
| Shoikeir, 20148 | FMD | Impaired | 34 | 10 |
| Sprung, 20148 | FMD | Impaired | 19 | 16 |
| Abali, 20158 | IMT, FMD | Impaired | 37 | 41 |
| Aldrighi, 20158 | FMD, IMT, dipyridamole stress RTMCE | β reserve and MBFR in PCOS + IR impaired | 18 with IR + 28 | 11 |
| Kahal, 20158 | IMT, reactive hyperaemic index, CRP, SP-selectin, sICAM, sVCAM | No alteration | 19 | 17 |
| Macut, 20158 | IMT | Impaired | 100 | 50 |
| Taskin, 20158 | FMD, IMT, CRP | FMD, CRP impaired | 128 | 148 |
| Yilmaz, 20158 | IMT (radial artery) | Impaired | 91 | 72 |
| Gursoy Calan, 20168 | IMT, CRP | Impaired | 144 | 144 |
| Yang, 20168 | FMD, ABI by BP cuff and Doppler instrument, ET-1 | Impaired | 21 | 21 |
| Bicer, 20178 | IMT, CRP | Impaired | 80 | 80 |
| Ramoglu, 20178 | IMT | No alteration | 52 | 45 |
| Tripathy, 20178 | FMD, IMT | Impaired | 124 | 117 |
| Calan, 201880 | IMT, CRP, TNF-α | CRP, TNF-α impaired | 75 | 75 |
| Wang, 201880 | FMD, NID, CRP | FMD, CRP impaired | 80 | 80 |
| Bicer, 201980 | IMT | Impaired | 82 | 82 |
| Rashad, 201980 | IMT, ICAM-1 | ICAM-1 impaired | 180 | 120 |
| Alexandraki, 202080 | AI, AIX@75, ET-1 | No alteration | 35 | 29 |

*Endothelial function determined as ratio between the arterial PWA following a 5-minute arterial occlusion in the forearm to the pre-occlusion value. AB = ankle-brachial index; AI = Augmentation Index; AIX@75 = AI corrected for heart rate; AO = abdominal aorta; aPWW = aortic pulse wave velocity; BP = blood pressure; CAC = carotid artery compliance; CCA = common carotid artery; CIMT = carotid intima-media thickness; CMR = cardiovascular magnetic resonance; CRP = high sensitivity C-reactive protein; ET-1 = endothelin-1 plasma levels; FMD = flow-mediated dilatation; ICAM = intercellular adhesion molecule; IL = interleukin; IMT = intima-media thickness; IR = insulin resistance; MBFR = myocardial blood flow reserve; NID = nitrate-induced endothelial-independent dilatation; PCOS = polycystic ovary syndrome; PWA = pulse-wave amplitude; PWV = pulse wave velocity; RA = renal arteries; RTMCE = high-resolution vascular ultrasound and real time myocardial contrast echocardiography; sICAM = soluble intercellular adhesion molecule; sVCAM = soluble vascular cell adhesion molecule; SP-selectin = soluble platelet selectin; TNF = tumour necrosis factor; US = ultrasonography; VA = vertebral arteries; VOP = venous occlusion plethysmography; WBC = white blood cells.
## Table 2: Studies on medical interventions in polycystic ovary syndrome populations

| Studies                  | Drug, treatment period                  | Number of patients treated | Findings                                                                 |
|--------------------------|----------------------------------------|----------------------------|--------------------------------------------------------------------------|
| Orio, 2005              | Metformin, 6 months                    | 32                         | ET-1 decreased; FMD increased; diameter after reactive hyperaemia decreased; IMT decreased |
| Diamanti-Kandarakis, 2005 | Metformin, 6 months                    | 20                         | ET-1 decreased; FMD increased; no change in NID                           |
| Sahin, 2007             | Metformin, 6 months                    | 20                         | No change in IMT                                                          |
| Heutling, 2008          | Metformin, 6 months                    | 21                         | No change in CRP/IL-6; IMT decreased                                      |
| Jensterle, 2008         | Rosiglitazone, 6 months                | 11                         | FMD increased; no change in NID                                           |
|                         | Metformin, 6 months                    | 15                         | FMD increased; no change in NID                                           |
| Romualdi, 2008          | Metformin, 6 months                    | 13                         | FMD increased                                                             |
| Luque-Ramírez, 2009     | OCP, 6 months                          | 15                         | No change in FMD/NID                                                      |
|                         | Metformin, 6 months                    | 20                         | No change in FMD/NID                                                      |
| Sahin, 2007             | Metformin, 6 months                    | 106                        | No change in IMT                                                          |
| Heutling, 2008          | Metformin, 6 months                    | 35                         | No change in CRP/IL-6; IMT decreased                                      |
| Jensterle, 2008         | Rosiglitazone, 6 months                | 11                         | FMD increased; no change in NID                                           |
|                         | Metformin, 6 months                    | 15                         | FMD increased; no change in NID                                           |
| Tan, 2009              | Metformin, 6 months                    | 21                         | IMT decreased                                                             |
| Mancini, 2010           | OCP with drospirenone, 6 months        | 28 (16 lean; 12 overweight)| FMD increased only in overweight; no change in ET-1                      |
| Palomba, 2010           | Metformin, 6 months                    | 24                         | ET-1 decreased; FMD increased; diameter after reactive hyperaemia decreased; IMT decreased |
|                         | Metformin, folate, 6 months            | 23                         | ET-1 decreased; FMD increased; diameter after reactive hyperaemia decreased; IMT decreased |
| Gode, 2011              | OCP, 6 months                          | 40                         | IMT increased; no change in FMD, NID, CRP                                 |
| Naka, 2011              | Pioglitazone, 6 months                 | 14                         | FMD increased                                                             |
| Naka, 2011              | Metformin, 6 months                    | 15                         | FMD increased                                                             |
| Raja-Khan, 2011         | Atorvastatin, 6 weeks                  | 9                          | CRP decreased; no change in FMD                                          |
| Bajuk Studen, 2013      | Spironolactone per 21-day for a cycle of 28 days, 6 months | 30                         | FMD increased                                                             |
| Tan, 2013              | Metformin, 6 months                    | 21                         | IMT decreased; no change in CRP                                           |
| Lie, 2012              | OCP, drospirenone, metformin, 6 months | 25                         | FMD increased; no change in CRP                                           |
| Karabulut, 2012         | OCP, 6 months                          | 30                         | No change in IMT                                                          |
| Pepene, 2012            | Ethinylestradiol/drospirenone, 6 months | 25                         | FMD increased IMT increased; no change in CRP                              |
| Vieira, 2012            | OCP, 6 months, 12 months               | 21                         | No change in FMD, IMT, carotid artery stiffness index improved at 6 and 12 months |
|                      | OCP spironolactone, 6 months, 12 months | 20                         | No change in FMD, carotid artery stiffness index; IMT increased at 12 months |
| Mohiydeen, 2013         | Metformin, 3 months                    | 17                         | No change in ED and EID microcirculation                                  |
|                         | Rosiglitazone, 3 months                | 18                         | No change in ED microcirculation; EID increased                           |
| Sprung, 2013            | 16-week exercise programme             | 10                         | FMD increased                                                             |
| Tan, 2013              | Metformin, 6 months                    | 21                         | No change in CRP/TFN-α; IMT decreased                                     |
| Shoikeir, 2014          | Laparoscopic ovarian drilling          | 34                         | FMD increased                                                             |
| Tan, 2014              | Metformin, 6 months                    | 21                         | No change in CRP/TFN-α, IL-6; IMT decreased                               |
| Kaya, 2015             | Metformin, OCP, 6 months               | 25                         | No change in FMD, IMT                                                    |
|                      | OCP, 6 months                          | 25                         | No change in FMD, IMT                                                    |
| Kahal, 2015            | Liraglutide, 6 months                  | 19                         | No change in CRP SP-selectin, sICAM, sVCAM, reactive hyperaemic index, IMT   |
| Orio, 2016             | OCP, 6 months                          | 47                         | No change in FMD, IMT, CRP                                               |
|                         | Structured exercise training programme, 6 months | 39                         | FMD increased; IMT decreased; CRP decreased                               |
| Yang, 2016             | Simvastatin, 6 months                  | 21                         | ET-1 decreased; FMD increased; AIB impaired                               |
| Wang, 2018             | Metformin, 3 months                    | 80                         | FMD increased; CRP decreased                                              |
| Ely, 2019              | Heat therapy, 8-10 weeks               | 9                          | CRP decreased; FMD increased; carotid wall thickness decreased; femoral wall thickness decreased |
| Talari, 2018           | Carnitine, 12 weeks                    | 30                         | IMT decreased; no change in CRP                                           |
|                      | 1,000 mg omega-3, 400 IU vitamin E, 12 weeks | 30                         | IMT decreased; CRP decreased                                              |
| Alexandraki, 2020      | Metformin, 6 months                    | 20                         | AIX@75 decreased; ET-1 decreased                                         |

*Endothelial function determined as ratio between the arterial pulse-wave amplitude following a 5-minute arterial occlusion in the forearm to the pre-occlusion value. AIB = ankle-brachial index; AIX@75 = Aix corrected for heart rate; CRP = high sensitivity C-reactive protein; ED = endothelium-dependent; EDI = endothelium-independent; ET-1 = endothelin-1 plasma levels; FMD = flow-mediated dilatation; IL = interleukin; IMT = intima-media thickness; NID = nitrate-induced endothelial-independent dilatation; OCP = oral contraceptive pill; sICAM = soluble intercellular adhesion molecule; sP-selectin = soluble platelet selectin; sVCAM = soluble vascular cell adhesion molecule; TNF = tumour necrosis factor.*
Figure 1: Search strategy

Search strategy used for the analysis of 104 studies on cardiovascular risk markers of women with polycystic ovary syndrome and 35 studies on medical interventions used to modify the cardiovascular risk factors of women with polycystic ovary syndrome. PCOS = polycystic ovary syndrome.

Overweight and obesity, defined as a body mass index (BMI) within the range of 25.00–39.99 kg/m² (mild 25.00–29.99, and severe >30.00–39.99 kg/m²), have been shown to be more prevalent in women with PCOS and are further associated with hyperinsulinemia and insulin resistance. The prevalence of obesity in patients with PCOS differs depending on ethnicity, being less prevalent in Europe and more common in the USA. However, both lean and obese women with PCOS display central fat distribution. Additionally, obese premenopausal women with PCOS have a 31–35% incidence of impaired glucose tolerance, whereas 7.5–10.0% develop overt diabetes. Moreover, other clinical entities, such as non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, as well as obstructive sleep apnoea and excessive daytime sleepiness, have been associated with insulin resistance and PCOS (Figure 2).

Parameters of cardiovascular disease

PCOS has been reported to bear an increased risk for atherosclerosis with a calculated increased risk (relative risk) of 7.4 for myocardial infarction. An early sign of the atherogenic process, which results in overt CVD, is endothelial dysfunction, which has been comprehensively studied in PCOS. Since PCOS has been suggested to represent a female subtype of metabolic syndrome, carrying a potential pre-atherogenic load, patients with PCOS have increased cardiovascular risk compared with age-matched controls. Myocardial infarction was recorded to be seven times more likely in patients with histopathological evidence of PCO, and cardiac catheterization studies have shown more extensive coronary artery disease in these patients than in women with normal ovaries. Furthermore, significant subclinical carotid atherosclerosis has been demonstrated on carotid artery ultrasound in women with PCOS.

This increased cardiovascular risk is likely to partly be a result of the metabolic disturbances associated with PCOS. Dyslipidaemia, diabetes (from impaired glucose tolerance to overt T2DM), and obesity are potentially cardiovascular risk factors that tend to cluster in women with PCOS. Many previous studies have documented abnormalities of insulin metabolism in both lean and overweight women with PCOS. Dyslipidaemia, insulin resistance and abdominal obesity are variable clinical features of PCOS which, irrespective of the presence of PCOS, contribute to the presence of metabolic syndrome with characteristic linkage to atheroma development and to overt risk for CVD. In addition, hypertension represents an uncommon and inconsistent finding in young women with PCOS, but its prevalence increases to 40% in the perimenopausal period. However, the epidemiological evidence of CVD events in relation to PCOS has not been confirmed.

An alternative explanation for the increased cardiovascular risk in PCOS is hyperandrogenism. Possible underlying pathophysiological mechanisms include a correlation between free testosterone and systolic BP and a link between increased androgens and abnormal lipid metabolism. Nonetheless, the association between hyperandrogenism and cardiovascular risk is not universally accepted. Previous studies of obese women with PCOS have shown that hyperinsulinemia
Cardiovascular Risk Markers in PCOS

Figure 2: Cardiovascular risk factors and metabolic factors in polycystic ovary syndrome

---

Endothelial function and polycystic ovary syndrome

The endothelium is the target organ for a variety of metabolic risk factors. It has been demonstrated that insulin exerts a direct hypertrophic effect on the vascular endothelium and on the smooth muscle cells. Abnormal vascular function has been shown in PCOS, and the syndrome has been associated with surrogate cardiovascular markers, such as increased serum levels of plasminogen-activator inhibitor 1 (PAI-1), elevated serum levels of C-reactive protein (CRP), and elevated advanced glycation end-products (AGEs) serum levels. The pathophysiology remains unclear but a number of mechanisms could be implicated to link endothelial dysfunction with insulin resistance, including disturbances of subcellular signalling pathways to insulin action or other potential unifying links.

Haemodynamic methods for endothelial function assessment in polycystic ovary syndrome

The endothelium plays a crucial role in regulating arterial function. Endothelial dysfunction is one of the best-understood preliminary steps in the development of atheromatous disease. It has been considered not only as a marker of early, possibly reversible, arterial abnormality, but also as a prognostic marker for future cardiovascular mortality.

Endothelial dysfunction can be studied by haemodynamic methods, like brachial flow-mediated dilatation (FMD) and venous obstructive plethysmography (VOP) on peripheral arteries, which both examine different sections of arterial bed (macro- and microcirculation, respectively) and should be considered complementary, providing different information.

The association between insulin resistance and endothelial dysfunction has been demonstrated consistently in subjects with T2DM, obesity and metabolic syndrome. Thus, at a mechanistic level, endothelial dysfunction appears to occur early in the insulin-resistant state; the progression of insulin resistance to diabetes in parallel to the progression of endothelial dysfunction to atherosclerosis. There are several mechanisms through which insulin resistance can adversely affect the endothelium. Insulin-resistant states, such as T2DM, are characterized by increased production of free fatty acids and proinflammatory cytokines, such as tumour necrosis factor-α, and leptin, which contribute to endothelial dysfunction. There is also evidence to suggest that insulin resistance induces increased oxidant stress, which may have an important pathogenic role.

Endothelial dysfunction and flow-mediated dilatation in polycystic ovary syndrome

Endothelial function can be estimated in conduit arteries (macrovascular function), non-invasively by high-resolution ultrasonography on the brachial artery, assessing FMD, an endothelial-dependent dilatation, which has been found to be correlated with coronary endothelial function, consequently representing an independent predictor of cardiovascular events. In the first published study to investigate endothelial function by FMD in patients with PCOS, no difference was shown compared to control women. However, few studies have confirmed these negative findings (Table 1). On the contrary, most studies undertaken in young women with PCOS, of normal weight or overweight and obese, confirm overt endothelial dysfunction. First, in young, lean women with PCOS, a 20% drop of FMD response has been shown, compared with normal women of a similar age and BMI. Furthermore, the combination of FMD and the biochemical assessment by endothelin 1 (ET-1) plasma levels to assess endothelial dysfunction in young, overweight insulin resistant women with PCOS and controls, with similar age and BMI, documented
impairment in women with PCOS, after exclusion of smooth muscle cells injury detected by nitrate-induced endothelial-independent dilatation (NID).16 Other parallel studies confirmed FMD impairment along with NID impairment, implying a global vascular deficit.15,16 In all these studies, insulin resistance had an impact on FMD,5,15,16 whilst a tendency of FMD to deteriorate from lean to overweight and to obese women with PCOS was observed, even without reaching statistically significant differences.16 Notably, in lean women with PCOS, FMD was found to be negatively influenced only by hyperandrogenaemia, and in overweight women by insulin resistance and hyperandrogenaemia.16 In an effort to correct for other cardiovascular risk factors, FMD and NID were assessed in a normoglycaemic, eulipidaemic, normal BP and normal glucose tolerance PCOS group, and a control group with comparable age, BMI and waist:hip ratio. FMD, but not NID, was impaired in women with PCOS who remained insulin-resistant.21 Finally, in young overweight women with PCOS, FMD was impaired compared with ovulatory controls matched for age and BMI, and this alteration was correlated to insulin resistance but not to the adipokines measured.20 Endothelial function has also been assessed by the use of novel technologies using cardiovascular magnetic resonance imaging, confirming pronounced endothelial dysfunction with normal endothelial independent dilatation in PCOS, compared with controls with similar age and BMI.27

We reviewed 39 studies that assessed FMD, and 27 (69%) of them, which included 1,359 patients with PCOS and 1,073 control subjects, showed impaired FMD in PCOS as opposed to 12 studies (including 448 patients with PCOS and 307 control subjects) that did not show any difference between these groups (Table 1).15-30 On the contrary, endothelial independent dilatation has been found to be mostly normal in women with PCOS (seven studies with 232 patients with PCOS and 211 control subjects versus three studies with 129 patients with PCOS and 72 controls).

Venous occlusion plethysmography and microvascular function in polycystic ovary syndrome

Microvascular function can be estimated in resistance arteries, and has been assessed in women with PCOS. In a HEC study in obese women with PCOS, a 50% reduced endothelial-dependent and insulin-mediated response of leg blood flow was found in the PCOS group, along with resistance to the vasodilating action of insulin, compared with the control group.2 This reduction was in response to intrafemoral injection of methacholine chloride. Insulin resistance was suggested to contribute to endothelial dysfunction, whereas BMI and androgens predicted endothelial dysfunction.7

Microvascular function has also been assessed, non-invasively, on resistance arteries by VOP on the forearm in women with PCOS who were normoglycaemic, eulipidaemic, and normotensive, compared with controls of comparable age, BMI and waist:hip ratio.21 The only parameter that differed between groups was time to peak hyperaemia, a parameter considered to reflect endothelial dysfunction, which was found protracted in the more insulin-resistant women with PCOS.21 Interestingly, time-to-peak hyperaemia was negatively related to SHBG, indirect index of hyperinsulinaemia and hyperandrogenaemia. Another study, using the same methodology, confirmed a shorter duration of reactive hyperaemia in the PCOS group, and a significant positive correlation between the duration of reactive hyperaemia and dehydroepiandrosterone-sulfate (DHEAS) levels in the PCOS group was reported, a finding that may support the cardioprotective effect of this androgen.25

Young women with PCOS have shown impaired endothelial-dependent dilatation as assessed by blood flow in the microvasculature of the forearm by the water displacement method during insulin infusion into the forearm in insulin-resistant PCOS, whereas insulin-sensitive women with PCOS responded similarly to controls.33 On the other hand, vascular function estimated by VOP assessing forearm vasodilatation in response to both endothelium-dependent (acetylcholine/bradykinin) and endothelium-independent (nitroprusside/verapamil) dilatators was not impaired in women with PCOS, compared with age- and weight-matched controls.21 Overall, forearm vasodilatation to all four drugs was reduced (<50%) in obese women with PCOS, compared with lean women with PCOS, but no significant difference in vascular function was detected between women with PCOS, compared with corresponding controls. On the other hand, obese women with PCOS exhibited markedly reduced vascular smooth muscle function compared with lean subjects with PCOS.23 Similarly, using a VOP technique to assess reactive hyperaemia of forearm microcirculation showed no evidence of endothelial dysfunction in obese women with PCOS compared with age- and weight-matched controls with a similar metabolic and inflammatory profile.19 Microvascular function has also been studied by wire myography, measuring the concentration response curve to norepinephrine before and after incubation with insulin in young women with PCOS and controls with similar cardiovascular risk factors. A functional defect in the vascular action of insulin ex vivo in patients with PCOS was demonstrated, suggesting a deleterious effect of insulin resistance at a vascular level in women without overt CVD. The defect in resistance arterioles was suggested to be specific to the action of insulin, since constriction to norepinephrine and relaxation to acetylcholine did not differ between women with PCOS and controls. In healthy subjects, insulin caused a dose-related attenuation of norepinephrine action; maximal response and sensitivity to norepinephrine decreased after exposure to physiological and supraphysiological concentrations of insulin. However, no response was observed at physiological doses in the vessels of women with PCOS, whereas at supraphysiological doses, sensitivity, but not maximum response, was altered, suggesting an abnormal resistance artery response to insulin, even in the absence of any other risk factor.4

In another study, microvascular function was assessed by forearm skin microvascular erythrocyte flux responses to cumulative iontophoretic doses of 1% (w/v) acetylcholine and 1% (w/v) sodium nitroprusside, using laser Doppler imaging in women with PCOS and age-matched controls.17 Basal microvascular perfusion was comparable in PCOS and controls, but the increase in skin microvascular perfusion in response to acetylcholine was blunted and peak acetylcholine-induced erythrocyte flux was reduced in women with PCOS compared with controls. Twenty per cent of acetylcholine response was attributed to insulin and BMI, while altered acetylcholine response was influenced by BMI and androgens levels. No difference in the response to nitrates was documented, implying an exclusively endothelial microvascular dysfunction.

Summarizing, based on different approaches of microcirculation assessment, it could be concluded that women with PCOS have impaired function in micro-vessels, but there are limited data regarding the association of this alteration with the hormonal and metabolic disturbances of the syndrome. On the other hand, among the four studies that have used plethysmography to assess microvasculature,21,30,32,35 only one (11 patients with PCOS versus 12 controls) did not show impairment in women with PCOS,16 whilst the other three studies
(66 patients with PCOS versus 53 controls) showed a clear difference\(^1\)\(^{12}\)\(^{13}\)\(^{14}\) (Table 1).\(^1\)\(^{15}\)\(^{16}\) In another two studies performed by the same group where reactive hyperaemia was assessed by an alternative technique, no difference was documented.\(^2\)\(^{10}\)

Another important manifestation to consider as a result of microvascular endothelial dysfunction would be pre-eclampsia, particularly the late-onset, where endothelial involvement has a key role in the pathogenesis.\(^10\) In fact, a recent prospective cohort study showed that pre-eclampsia, gestational diabetes and lower birth weight among newborns were significantly higher in the women with PCOS compared with healthy controls, identifying higher BMI and hyperandrogenaemia as the strongest predicting factors.\(^10\)

**Intima-media thickness and polycystic ovary syndrome**

Intima-media thickness (IMT) is a morphological marker of vascular injury.\(^10\) An increase in carotid artery IMT has been observed in women with PCOS, and especially in middle-aged women.\(^1\) In 16 premenopausal women, aged >40 years old with a history of PCOS, carotid IMT was increased, compared with a control group of similar age.\(^1\) Nevertheless, this difference was observed between patients and controls, up to the age of 45 and not in younger groups. PCOS was found to represent the unique prognostic factor of variable IMT in multiple regression analyses, while, after correction for age and BMI, the correlations of PCOS changed slightly, implying that part of the observed relation between PCOS and IMT is likely due to central obesity and hyperinsulinaemia.\(^1\) In a study of 125 women with PCOS and 142 controls, there was a significantly higher prevalence of carotid index of atheroma plagues in women with PCOS (7.2% versus 0.7%) compared with controls.\(^1\) The difference in carotid IMT between women with PCOS and controls was detected in women aged >45 years, compared with women aged 30–44 years. Since CVD is characterized by long-term subclinical latency, metabolic disturbances are becoming overt at middle-age only. PCOS and aging appear to interact, resulting in deleterious changes to the carotid arterial wall, since differences in lipid levels between women with PCOS and controls are blunted approaching the menopausal period.\(^14\)\(^{15}\)\(^{16}\) As expected, contradictory data have been published in younger women.\(^1\)\(^{15}\)\(^{16}\)

Notably, a clinical study investigated the haemodynamic changes in the medial cerebral artery and the internal carotid artery in 28 young women with PCOS and polycystic ovaries (PCO) compared to 24 healthy controls.\(^1\) Blood flow rate and pulsatility index were measured by transcranial Doppler ultrasonography, but no significant differences in arterial pulse wave amplitude following a 5-minute arterial occlusion by non-invasive electron beam computed tomography (EBCT) in 36 women with PCOS, compared with 71 controls of a similar age and BMI.\(^1\)\(^{18}\) Similarly, a higher prevalence of coronary artery calcium (45.9% versus 30.6%) and aortic arterial calcification (68.9% versus 55.3%), measured by EBCT, was documented in women with PCOS compared with controls in a prospective study, whereby women were screened in 1993–1994 and re-evaluated in 2001–2002.\(^1\) After adjustment for age and BMI, PCOS was found to be a significant predictor of coronary artery calcium, but not aortic arterial calcification. In addition, an increased risk of metabolic syndrome was reported in women with PCOS.\(^1\)

In 60 women (20 with PCOS, 20 with PCO and 20 healthy controls), compliance and stiffness indices were assessed in the common and internal carotid arteries using ultrasonographic methods. An impairment was reported in women with PCOS, compared with controls.\(^2\)\(^{10}\) Furthermore, macrovascular function at the brachial artery (but not at the aorta), as well as microvascular function, have been found to be impaired, suggesting increased vascular stiffness and a functional defect in the vascular action of insulin ex vivo in patients with PCOS.\(^2\)\(^{10}\)

This has been confirmed by other studies evaluating arterial stiffness, where insulin resistance was an independent prognostic factor of pulse wave velocity and arterial stiffness in women with PCOS.\(^2\)\(^{10}\) Endothelial function has also been assessed using peripheral arterial tonometry methodology, namely a post-ischaemia reactive hyperaemia technique that determines endothelial function as the ratio between the arterial pulse wave amplitude following a 5-minute arterial occlusion in the forearm to the pre-occlusion value, in normal-weight young women with PCOS compared with a control group with similar BMI.\(^2\)\(^{10}\) However, taken together, these parameters (arterial stiffness, augmentation index, resistance indices, aortic wave reflections) showed contradictory results (Table 1).\(^2\)\(^{10}\)

Cardiac function parameters have been also investigated in PCOS. In 26 lean young women with PCOS (mean age 22.8 ± 0.9 years; mean BMI 23.0 ± 0.8) and 11 healthy slightly older women with similar BMI (mean age 26.3 ± 1.7 years; mean BMI 22.9 ± 0.9), parameters
cardiac output were estimated by ultrasonographic method; impaired parameters of systolic function, as well as their negative association with fasting insulin, were observed in the PCOS group without impairment of diastolic function.219 In another study, several diastolic and systolic parameters were impaired in women with PCOS; however, women with PCOS had higher total cholesterol and LDL-C levels compared with controls.220 In another study, 30 women with PCOS differed in diastolic cardiac parameters compared with 30 older healthy women, and hyperinsulinaemia and lipidaemic load were higher in the PCOS group.214 Another study found that ultrasonographic cardiac parameters were evaluated and women with PCOS had higher left atrium size and left ventricular mass index, lower left ventricular ejection fraction and early-to-late mitral flow velocity ratio than controls.225 When patients and controls were grouped according to weight into normal weight, overweight and obese groups, differences in the metabolic profile and cardiac findings persisted, but a progressive impairment of metabolic profile and echocardiographic pattern was seen in patients with normal weight compared with those with obesity. Young women with PCOS had a significantly increased cardiac size compared with controls, and other structural, systolic and diastolic function cardiac parameters were altered. Notably, most cardiac abnormalities persisted even in young patients with normal weight, suggesting that the pathogenesis of cardiac abnormalities in PCOS is not only dependent on BMI, but also to insulin resistance indices.226

Finally, autonomic innervation of the heart, evaluated non-invasively with power spectrum analysis of heart rate variability from electrocardiographic recordings, can be affected in women with PCOS with increased sympathetic and decreased parasympathetic components of heart rate variability.227

Biochemical studies for endothelial function assessment in polycystic ovary syndrome

Endothelial dysfunction can also be assessed biochemically by ET-1 plasma levels measurements. In 2001, Diamanti-Kandarakis et al. showed that ET-1 plasma levels are increased in women with PCOS.210 ET-1 plasma levels were positively related to androgen levels and negatively to insulin sensitivity, assessed by HEC (the gold standard assessment of insulin sensitivity), suggesting insulin resistance and hyperinsulinaemia implication in altered endothelial function. These results were later confirmed.211,212 Overall, we reviewed seven studies that assessed ET-1 levels, five (71%) of which included 109 patients with PCOS and 83 controls, and showed increased ET-1 levels in PCOS, whereas two studies (including 59 women with PCOS and 49 controls) did not show any difference between the groups (Table 1).213–215

Markers of low-grade inflammation and certain components of the haemostatic system have been also shown to predict atherosclerotic risk in insulin-resistance states such as metabolic syndrome and T2DM.228,229 Recent advances in basic science have demonstrated a fundamental role for inflammation in mediating all stages of this disease, from initiation through progression of atherosclerosis. The current notion that inflammation and immune response contribute to atherogenesis has garnered increased interest.227 Evidence of low-grade chronic inflammation in PCOS is indicated by the presence of several elevated markers such as CRP levels,230–232 inflammatory cytokines,233–235 increased leukocyte count,236 and adhesion molecules237 (Table 1).213–215

A number of studies in humans have assessed the relationship between endothelial function and markers of inflammation, but the results have been variable and sometimes conflicting regarding the relationship between CRP and brachial artery FMD, or between CRP and coronary endothelial dysfunction. In sum, we reviewed 34 studies that assessed CRP levels; 21 (62%) of them (including 1,589 patients with PCOS and 1,209 control subjects) showed increased CRP levels in PCOS, as opposed to 13 studies (including 591 PCOS and 473 control subjects) that did not show any difference between the groups (Table 1).213–215

Management of endothelial function impairment in polycystic ovary syndrome: Treatment with insulin sensitizers

A number of mechanisms have been implicated to link endothelial dysfunction with insulin resistance, including disturbances of subcellular signalling pathways to insulin action or other potential unifying links.212–214 Therefore, utility of insulin sensitizers can be justified in patients with PCOS, and specifically for endothelial function improvement, and we will discuss their function along with other therapeutic agents that have been used for PCOS management (Figure 3).

Metformin

Metformin is a biguanide agent that has been used in the treatment of T2DM. It lowers blood glucose levels by significantly reducing hepatic glucose production and by increasing peripheral glucose utilization. It lowers serum insulin levels and improves insulin sensitivity, not only by its glucose-lowering effect, but also by increasing insulin-binding to its receptor.227 Moreover, the drug appears to enter into the cells and enhance the tyrosine phosphorylation of the intracellular portion of the insulin receptor and of insulin receptor substrate (IRS) proteins.227 Recently, it has been suggested that IRS genotype may modulate the response to metformin treatment in women with PCOS.228

A number of studies have been published investigating the effect of metformin on insulin resistance in women with PCOS. One study showed that metformin treatment in 26 obese women with PCOS for 2 months reduced hyperinsulinaemia and systolic BP, and improved hormonal and reproductive abnormalities.229 The first European study, published in 1998, confirmed the increase in insulin sensitivity (glucose utilization rate) using the HEC, irrespective of the changes in body weight, after administration of 1,700 mg metformin for 6 months in 13 obese women with PCOS.230 Metformin has been shown to improve lipid profile, mainly by increasing serum HDL-C concentrations.231–233 However, some studies have shown only a negligible or no effect on lipids in women with PCOS.234,235 The mechanisms by which metformin improves lipid profile are not clear; it has been suggested to reduce lipid uptake or synthesis in the intestine and in the hepatocytes.236–238 The improvement of obesity, especially abdominal obesity, with a subsequent decreased release of free fatty acids from adipose tissue observed during metformin therapy could also partly explain the improvement of lipid profile during metformin treatment, at least in obese women.239

A study investigating the effect of metformin on endothelial function in obese and non-obese women with PCOS and increased plasma ET-1 levels, revealed a statistically significant reduction of those levels in both groups after 6 months of treatment.240 Interestingly, hyperandrogenaemia, as well as insulin resistance (assessed by HEC), were improved in parallel with ET-1 levels post-metformin without a concomitant reduction in BMI. Later, the administration of 1,700 mg metformin daily for 6 months in young overweight women with PCOS normalized FMD on the brachial artery, and at the same time significantly decreased ET-1 plasma levels.241 On the other hand, when metformin was used for 3 months, no improvement was observed in endothelial function assessed using peripheral arterial tonometry methodology in normal-weight
Figure 3: Therapeutic strategies in polycystic ovarian syndrome

| Metformin | Thiazolidinediones (rosiglitazone/pioglitazone) | TZDs | Inositols |
|-----------|-----------------------------------------------|------|-----------|
| ↓ Blood glucose | ↓ Ovarian steroidogenesis | ↓ IR | ↓ Androgens |
| ↓ Gluconeogenesis | ↓ Insulinemia | ↓ Lipolysis | ↓ Hirsutism |
| ↓ Insulin | ↓ Release of FFAs | ↓ ROS | ↓ Testosterone |
| ↓ BP | ↓ ET-1 | ↓ Peripheral glucose uptake | ↓ CRP |
| ↓ Lipid uptake/synthesis, FFAs | ↓ TNF-α | ▲ Improve endothelial function | ▲ Improve ovulation |
| ↓ ET | ▲ HDL-C | ▲ Improve FMD | |
| ↓ Low-grade chronic inflammation | ▲ DCI | ▲ Improve FMD | |
| ↓ Adipose tissues | ▲ Microvascular function | ▲ Normalize FMD | |
| ▲ AGEs | ▲ Coronary flow reserve | ▲ IMT | |
| ▲ HDL-C | ▲ VCAM-1/ICAM-1 | ▲ Other | |
| \* Normalized FMD | ▲ TZD | ▲ Suggested combination MI/DCI 40:1 ratio | |

✓ improved; ▲ increased; ↓ decreased/reduced; ▲ increased.

AGEs = advanced glycosylated end-products; BP = blood pressure; CRP = C-reactive protein; DCI = D-chiro-inositol; ET-1 = endothelin 1; FFAs = free fatty acids; FMD = flow-mediated dilatation; GDM = gestational diabetes mellitus; HDL-C = high-density lipoprotein cholesterol; ICAM-1 = intercellular adhesion molecule 1; IMT = intima-media thickness; ins = insulin; IR = insulin resistance; M6 = myo-inositols; PCOS = polycystic ovary syndrome; ROS = reactive oxygen species; S/D = systolic/diastolic; TNF-α tumour necrosis factor α; TZDs = thiazolidinediones; VCAM-1 = vascular cell adhesion protein 1.

![Figure 3: Therapeutic strategies in polycystic ovarian syndrome](image)

In a randomized study, a significant reduction in serum CRP levels by 31% was shown in obese patients and 56% in obese patients, post-metformin administration. Adhesion molecules have also been reduced after 6 months of treatment with metformin in 62 patients with PCOS, independently of body weight changes. In addition, AGEs, a complex and heterogeneous potent atherogenic group of molecules, and their receptors, were found to be elevated in young women with PCOS. Although the mechanism implicated in this phenomenon is not clear, it could be due to insulin action defects; dietary-exogenous AGEs may also contribute to it. Metformin administration for 6 months reduced, but did not normalize, AGEs serum levels compared with pre-treatment levels; this effect of metformin, if confirmed, could be of clinical significance in improving adverse long-term sequelae of the syndrome. Metformin was also administered in women with PCOS with and without insulin resistance, and improved microvascular function and coronary flow reserve after 6 months, as assessed by transthoracic second-harmonic Doppler echocardiographic methodology.

We reviewed metformin administration in 19 study groups, in a total number of 465 women with PCOS for a median period of 6 months’ time (range 3–6 months). Oral contraceptive pills were co-administered in two studies: FMD improved (increased) in 8 out of 10 (80%) studies, ET-1 improved (decreased) in all the four studies in which this was assessed, IMT improved (decreased) in 8 out of 10 (80%) studies, and amelioration in reactive hyperemia in two out of the three studies in which this was assessed. These findings indicate the beneficial effect that metformin exerts on micro-, macro-circulation as well as on the structural arterial properties of young women with PCOS (Table 2).

**Cardiovascular Risk Markers in PCOS**

**Table 2**

| Markers | doi | Title |
|---------|-----|-------|
| CRP     | 177 | In addition, AGEs, a reduced after 6 months of treatment with metformin in 62 patients with young women with PCOS. The exact mechanism, direct or indirect, by which metformin acts on endothelium, has not been clarified. Nevertheless, metformin treatment has been associated with a significant decrease of low-grade chronic inflammatory markers.

Thiazolidinediones include three drugs: troglitazone, rosiglitazone and pioglitazone. They act by enhancing glucose uptake in adipose and muscle tissues. In comparison to the effect observed by metformin, thiazolidinediones increase more peripheral glucose uptake and decrease lesser hepatic glucose output. They improve insulin sensitivity and they decrease not only circulating insulin but also the release of free fatty acids and TNF-α from adipose tissue. At the cellular level they bind and activate the peroxisome proliferator activated receptor-γ (PPAR-γ) and they induce the transcription of genes that are involved in glucose control and lipid metabolism.

In women with PCOS, the therapeutic effect of insulin sensitizers is mediated by the reduction of hyperinsulinaemia and insulin resistance, and consequently by alteration of ovarian steroidogenesis. Moreover, an inhibitory effect in steroidogenesis has been demonstrated on humanized yeast cells, and thiazolidinediones (rosiglitazone and pioglitazone) have been found to inhibit estradiol and testosterone production in cultured human ovarian cells. Dunaif was the first to study the effects of troglitazone on metabolic profile in women with PCOS in a double-blind, randomized, 3-month trial of two doses (200 mg, 400 mg) of troglitazone. Hyperinsulinaemia, as well as insulin sensitivity, was assessed by a frequently sampled intravenous glucose tolerance test and improved significantly.

In a later study, troglitazone was administered for 3 months in 13 obese women with PCOS and found to have impaired endothelial function, as assessed by leg blood flow responses to graded intraluminal artery infusion of the endothelium-dependent vasodilator methacholine chloride. Basal leg blood flow was found unchanged after troglitazone,
but the increase in leg blood flow in response to methacholine chloride in PCOS was markedly more pronounced after treatment and was similar to that observed in obese women without PCOS. It was suggested that troglitazone improves endothelial function by reducing lipolysis, reactive oxygen species production, ET-1 secretion or vascular inflammation. Confirming the above results, as troglitazone was retracted from clinical use, rosiglitazone was administered in 31 young normal to overweight women with PCOS for 1 year and it was observed to improve endothelial function, and at the same time, insulin sensitivity indices, hyperandrogenaemia, hyperinsulinaemia and systemic inflammation, when assessed by CRP.

Overall, in two of the included studies, where rosiglitazone was given for a median time of 4.5 months (range 3–6 months), FMD was improved, but not NID, in one study and in the second study using a different method to assess microcirculation, no improvement was noted in endothelial-dependent function as opposed to a significant improvement in endothelial-independent function. On the contrary, in the study of 14 women with PCOS with pioglitazone administration, FMD was improved.

Other agents

Oral contraceptive pills

Oral contraceptive pills represent a traditional treatment for the hyperandrogenic sequelae of women with PCOS. We reviewed 13 study groups of women with PCOS receiving oral contraceptives, who were compared, or not, with other treatments. Metformin was co-administered in two of the studies included. FMD improved in three (27%) out of 11 study-groups; ET-1 levels did not improve in one study where this was assessed; whilst IMT improved in three (33%), but deteriorated in one out of nine study groups (Table 2).

Similarly, CRP levels were not reduced in all four study groups that assessed it. A meta-analysis including three randomized controlled studies that compared oral contraceptives containing oestrogen (ethinylestradiol) with progesterone drospirenone or chlorormadinone acetate, showed a beneficial effect of ethinylestradiol/drospirenone over ethinylestradiol/chlormadinone acetate in reducing androstenedione levels and total testosterone after 3 months, and Ferriman–Gallwey score after 6 months.

Although oral contraceptive pills improve clinical and biochemical hyperandrogenism, there are concerns about worsening the metabolic and inflammatory profile of these patients. Adipokines, such as adiponectin, visfatin and resistin, which are considered indices of both inflammation and insulin resistance, have deteriorated in women with PCOS after 6 months of oral contraceptive treatment compared with controls. Additionally, the use of oral contraceptives in obese and non-obese patients with PCOS with impaired glucose tolerance increases asymmetric dimethylarginin, which is a marker of endothelial dysfunction and CRP levels, so creates an increase in metabolic risk. On the other hand, the combination of oral contraceptive pills with metformin in overweight women with PCOS may lower this risk, as it seems to improve both hyperandrogenism and inflammatory parameters. Similar results have been shown when metformin has been combined with anti-androgens containing oral contraceptives, which may improve androgen and insulin resistance. However, this addition of metformin has achieved a reduction in adhesion molecules as markers of low-grade chronic endothelial inflammation and CVD.

Statins and glucagon-like peptide-1

Statins have been also investigated in PCOS. Atorvastatin failed to improve FMD but reduced CRP in nine women with PCOS in only 6 weeks, whereas simvastatin given for 6 months improved FMD and hormonal profile, and reduced ET-1 levels. Liraglutide has also been trialled for a 6-month period, but no overt benefits were seen in reactive hyperaemic index, IMT, CRP and adhesion molecules. Although the reproductive and hyperandrogenaemic profile of these patients was not examined in these studies, a very recent meta-analysis of nine randomized controlled trials (613 patients) showed a superiority of atorvastatin compared with all other treatments (simvastatin, spironolactone, oral contraceptives and metformin) to reduce total testosterone levels in patients with PCOS.

Spironolactone

Spironolactone, due to its anti-androgenic and aldosterone antagonistic effects, has been explored among PCOS treatment strategies. It has been shown to be effective in improving both reproductive and metabolic parameters, equally to pioglitazone and superiorly to metformin, especially when combined with high doses of vitamin D supplementation. Thirty non-obese patients with PCOS with normal mean aldosterone plasma levels had significantly lower FMD compared with 20 BMI-matched control subjects, but this difference was reversed after 6 months’ therapy with spironolactone.

Inositols

Inositols are polyols with insulin-sensitizing properties. Myo-inositol is the most common naturally occurring stereoisomer, which can be converted to a second stereoisomer, D-chiro-inositol (DCI). Inositols are involved in insulin signalling, with both myo-inositol and DCI functioning as insulin second messengers, although they mediate different actions of insulin in humans. Specifically, myo-inositol is considered safe in pregnancy and beneficial in reducing insulin resistance, systolic/diastolic BP and the risk of gestational diabetes, which have a higher incidence among women with PCOS. The clinical experience with DCI is inferior to myo-inositol, but more interesting data are being published regarding the combination of the two. A recent meta-analysis evaluated the efficacy of treatments with myo-inositol, alone or combined with DCI (40:1 ratio between myo-inositol and DCI) for 12–24 weeks, in nine randomized controlled trials comprising 247 cases and 249 controls. Significant improvement in metabolic parameters (insulin levels, HOMA-IR), and to a lesser extent testosterone levels, was seen after inositol supplementation.

Moreover, the combination of myo-inositol and DCI in a 40:1 ratio seems to improve the reproductive profile of these patients by restoring ovulation in 62.5%. The synergistic effect of metformin with myo-inositol, as opposed to metformin alone, was also investigated in women with PCOS undergoing ovulation induction, and showed not only an increase in live birth rate, but also an improvement in insulin sensitivity and reduced requirements for metformin dosage.

General considerations

Taken altogether, controversial data exist regarding the presence of endothelial dysfunction and arterial structure impairment in women with PCOS, with certain studies reporting no impairment and others showing significant alterations. Differences in cardiovascular risk factors (principally differences in metabolic profile between patients and controls) among the various populations studied might explain these discrepancies. However, endothelial dysfunction seems to be a well-recognized trait of PCOS in both micro- and macro-circulation, although not all the investigators agree.

Regarding the pathophysiology of the phenomenon, it has been postulated that insulin-resistant individuals exhibit resistance to both the metabolic and vascular actions of insulin. PKA, a key intracellular signalling step of insulin action, has been shown by in vivo studies.
to be defective in the insulin-resistant state, as well as in PCOS. The signalling pathways by which insulin mediates glucose uptake and nitric oxide production converge at the PI3K/Akt. Consequently, disruption of this pathway may link different pathogenic mechanisms, leading to impaired glucose utilization and endothelial dysfunction. Furthermore, hyperinsulinaemia drives ET-1 production by endothelial cells via the PI3K pathway, further impairing endothelial function by competing with NO; ET-1 has been shown to inhibit insulin signalling via the same pathway. ET-1 levels have been found increased in women with PCOS. These findings support the hypothesis that, in women with PCOS, the abnormal vasculature status could be due to impaired insulin vasodilator functions, mediated by PI3K.

On the other hand, there are data that support a role of hyperandrogenaemia in vascular reactivity in PCOS, but the mode of action of androgens remains unknown. Androgen receptors are known to exist on the vessel wall, and a direct effect of androgens in the vasculature cannot be excluded. Alternatively, androgens may act synergistically with insulin resistance, inflammatory cytokines or angioconstrictive peptides on endothelial function. Androgens may promote monocyte adhesion to endothelial cells, a proatherogenic effect mediated, at least in part, by increased endothelial vascular cell adhesion protein-1 (VCAM-1) expression, which has been found elevated in women with PCOS. There are also some interesting data favouring a compensatory role of adrenal androgens and particularly DHEAS for the adverse effects of dyslipidaemia and insulin resistance.

Recently, correlations between various cardiovascular risk factors, insulin resistance, hyperandrogenaemia, endothelial dysfunction and chronic inflammation have been detected in PCOS populations, supporting the concept of their interplay on the vascular bed pathophysiology of women with PCOS. Whether these interactions could contribute to long-term sequelae, namely in CVD events, has not been clarified. Nevertheless, the principal candidates’ effectors for cardiovascular risk factors and for endothelial dysfunction presence remain insulin resistance and hyperandrogenaemia, the basal characteristics of PCOS.

Hypotheses for endothelial dysfunction pathogenesis also implicate a number of additional atherogenic molecules. Increased expression of soluble intercellular adhesion molecule-1 and soluble VCAM-1 found in patients with PCOS plays an important role in focal leukocyte accumulation in subendothelial regions of atheroma. However, the causes of elevated inflammatory molecules remain unclear. The associations between chronic inflammation and endothelial dysfunction with features of PCOS, such as obesity, may have an additional aggravating role. On the other hand, high testosterone levels have been found to induce VCAM-1 expression.

The central role of insulin resistance and hyperandrogenaemia can also be certified by the beneficial effects of the action of insulin sensitizers on the endothelium, since those agents improve those pathogenic effectors. Recent studies make efforts to shed light on mechanisms of action of insulin-sensitizing agents on the endothelium. Notably, in one study, metformin was shown to improve endothelial function, by lowering atherogenic molecules, like adhesion molecules or AGEs serum. It has been suggested that metformin has an inhibitory effect in the glycation process by interfering with the synthetic pathway of AGEs through the trapping of methylglyoxal and of other dicarbonyl compounds responsible for the glycation process in vivo. Therefore, the action of metformin may lead to reduced synthesis and/or increased detoxification of AG metabolites. Regarding the clearance of AGEs, intact PI3K activity is required for the activation of the macrophage scavenger receptor, which is one of the major mechanisms for their clearance. A key intracellular signalling step of insulin action, has been shown to be defective in an insulin-resistant state and in PCOS. The decreased PI3K activity present in insulin-resistant PCOS may link the pathogenic mechanisms of PCOS insulin resistance with decreased AGE clearance. Nevertheless, a mechanism independent from the antihyperglycaemic effect has been shown for metformin in preventing microvascular alterations.

Inositol also have insulin-sensitizing properties that may be proved to be of clinical significance, with or without metformin co-administration. However, FMD has been improved by spironolactone administration alone as opposed to its co-administration with oral contraceptive pills, where no improvement was seen in 6 months in the context of FMD, carotid artery stiffness index and IMT; whereas at 12 months, a deterioration in IMT was observed. Notably, the combination of oral contraceptives, drospirenone and metformin for 6 months resulted in FMD improvement, possibly due to the impact of metformin. The addition of drospirenone in oral contraceptives also improved FMD but deteriorated IMT without alteration of CRP levels, implying an ill-defined role for drospirenone.

Finally, lifestyle amendments, such as a structured exercise training programme, heat therapy, carnitine or vitamin administration, as well as laparoscopic ovarian drilling, improved FMD and/or IMT, implying that the role of lifestyle changes or hormonal control are necessary for a better cardiovascular risk-factor profile.

**Conclusion**

It can be concluded that endothelial dysfunction is more likely to occur among patients with PCOS than in healthy controls. In order to confirm this widely accepted observation, there is a need for large-scale, well-designed prospective studies of cardiovascular outcomes in PCOS for a better understanding of the role that the cardinal features of PCOS, insulin resistance and hyperandrogenaemia may have on vascular function. Long-term cohort studies are particularly needed in the different phenotypes of PCOS, in order to provide information for the target-to–treat in each phenotype, since different modes of treatments may be used in different sub-phenotypes with differences in the cardiometabolic or reproductive risk profile of the syndrome.

Since, there are no universal specific diagnostic signs or characteristic phenotypes that could preclude the response to different therapeutic modalities, it seems important to assess the predominant symptoms and risk factors in the metabolic and reproductive aspects of each woman, with the aim of producing individualized treatments. Based on the pathophysiological role of insulin resistance, insulin-sensitizing agent administration can be justified, particularly as a treatment of choice in hyperinsulinaemic obese or non-obese women. Other interventions, such as lipid-lowering agents, antioxidants, oral contraceptives and anti-androgen agents have to be further investigated in order to assess their role as therapeutic tools in PCOS management, since their effects on the cardiovascular properties in PCOS are missing.

Finally, large-scale, long-term follow-up studies should be designed based on the established cardiovascular risk factors in order to identify the best clinical and biochemical markers that could be used in clinical practice for the prevention of a potentially ‘silent’ trigger of CVD, which can occur early in life, masked behind hormonal and reproductive signs and symptoms.
2. Diamanti-Kandarakis E, Dunaif A. New perspectives in reproductive endocrinology. Fertil Steril. 2005;84:1335–1344.

30. Lowenstein L, Damti A, Pillar G, et al. Evaluation of endothelial function and the beneficial effect of metformin therapy. J Clin Endocrinol Metab. 2007;92:4218–4223.

32. Cascella T, Palomba S, De Sio I, et al. Visceral fat is associated with endothelial dysfunction in young women with polycystic ovary syndrome. Eur J Endocrinol. 2008;159:397–403.

39. Carmina E, Guastella E, Longo RA, et al. Correlates of increased prothrombin fragment 1 + 2 concentrations and cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril. 2005;84:2037–2041.

40. Ciccone MM, Favale S, Bhuva A, et al. Anteroposterior diameter of the infrarenal abdominal aorta is higher in women with polycystic ovary syndrome: Vasc Health Risk Manag. 2009;5:161–167.

41. Guasch-Ferré M, Estruch R, Ros E, et al. Association between subclinical cardiovascular disease and lipocalin-2 serum levels is increased in polycystic ovarian syndrome patients. J Obes. 2012;2012:670784.

50. Nakai K, Kanatsurana S, Hasegawa M, et al. Effect of ethinylestradiol and gestodene on the development of subclinical cardiovascular disease in young non-obese women with polycystic ovary syndrome: a pilot study. Gynecol Endocrinol. 2012;28:84–89.

51. Battaglia C, Battaglia B, Mancini F, et al. Ultrasonographic evaluation of body fat distribution and vascular parameters in women with polycystic ovary syndrome. Hum Reprod. 2007;22:1105–1110.

52. Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod. 2007;22:3977–3983.

53. Cascella T, Palomba S, De Sio I, et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. 2008;23:1539–1544.

54. Erdoğan M, Kaya E, Yaylali GF, et al. Serum aldosterone concentration and cardiovascular risk factors in women with polycystic ovary syndrome. Fertil Steril. 2008;90:1401–1405.

55. Escobar-Morreale HF. Fibrinolytic activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilation in mainly non-obese women with polycystic ovary syndrome. Fertil Steril. 2012;98:219–223.
market for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome.

86. Rees, S., Coulson, D., Dunlop, F., et al. Central arterial stiffness and insulin resistance in polycystic ovary syndrome: a longitudinal study and an oral glucose challenge in humans. Clin Endocrinol (Oxf). 2013;78:418-25.

87. Tan BK, Chen J, Hu J, et al. Circulatory changes of the novel adiponectin-transporter monocarboxylate transporter-4 and its relationship with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk. Hum Reprod. 2016;31:170-80.

88. Abali R, Tasdemir N, Alpsoy S, et al. No relationship between plasma adiponectin and insulin resistance in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95:1861-9.

89. Palomina S, Balso, A., Galalita, U., et al. Effects of metformin on microvascular endothelial function in polycystic ovary syndrome. Arch Gynecol Obstet. 2011;284:923-9.

90. Rana Khan N, Kusumastari, A., Wijaya, C. et al. Effects of atorvastatin on endothelial function and adiponectin in women with polycystic ovary syndrome. Arch Endocrinol Metab. 2011;65:18-21.

91. Bajaj, Studen K, Jersterie Sever, M. Palmeri, M. Cardiovascular risk and subclinical atherosclerotic burden in polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102:2141-9.

92. Moghetti P, Bot F, Bonin C, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:1273-6.

93. Polak K, Grozy A, Simonian C, et al. Markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2019;42:947-52.

94. Balen AH, Conway GS, Kaltas, G. et al. Polycystic ovary syndrome: the spectrum of a disorder in 1741 patients. Hum Reprod. 1995;10:2017-21.

95. Krohnenhauer ES, Key, T., Kastl-Miller, M. et al. Prevalence of the risk factor model based on a prospective population study of women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-82.

96. Taboada, Guzman, C., et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Contraception. 2013;88:415-21.

97. Strothkamp J, Hasler B, Demart T. Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in polycystic ovary syndrome. Contraception. 2006;73:65-70.

98. Kichkeng, S. Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:1272-76.

99. Balen AH, Conway GS, Kaltas, G. et al. Polycystic ovary syndrome: the spectrum of a disorder in 1741 patients. Hum Reprod. 1995;10:2017-21.
development of symptomatic peripheral arterial disease in men. Circulation. 2002;106:926–5.
256. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.
257. Steinberg HO, Chaker H, Learning R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601–10.
258. Rahbar S, Natarajan R, Yerneni K, et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta. 2000;301:65–77.
259. Betowski F, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab. 2003;29:659–63.
260. Betowski F, Howell SK, Touchette AD, et al. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 1999;48:198–202.
261. Ruggiero-Lopez D, Leonetti M, Moinet G, et al. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol. 1999;58:1765–73.
262. Kiho T, Kato M, Usui S, Hirano K. Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. Clin Chim Acta. 2000;301:139–45.
263. Tanaka Y, Uchino H, Shimizu T, et al. Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol. 1999;376:77–22.
264. Sano H, Higashi T, Matsumoto K, et al. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J Biol Chem. 1998;273:8630–7.
265. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. UKPDS 34. UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–65.